CeNeRx BioPharma Initiates Phase II Clinical Trial Of Its Novel Antidepressant Agent Tyrima(TM) CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, announced that it has initiated a Phase II clinical trial for its lead product candidate Tyrima(TM) for the treatment of major depressive disorder (MDD). Tyrima is a selective and reversible member of a novel class of
drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A (MAO-A).
Source: www.medicalnewstoday.comAbdominal Aortic Aneurysm More Likely In Women Who Smoke New research published on bmj.com has more bad news for women smokers. Compared to women who have quit smoking, women smokers are four times more likely to have an abdominal aortic aneurysm repair or rupture. Further, women smokers are eight times more likely to have the condition than women who have never smoked.
Source: www.medicalnewstoday.com
# posted by Network @ 5:00 PM
